{"id":48430,"date":"2025-11-17T14:05:36","date_gmt":"2025-11-17T06:05:36","guid":{"rendered":"https:\/\/flcube.com\/?p=48430"},"modified":"2025-11-17T14:05:36","modified_gmt":"2025-11-17T06:05:36","slug":"zelgen-biopharmas-zg006-alveltamig-receives-fda-orphan%e2%80%91drug-designation-for-neuroendocrine-carcinomas","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48430","title":{"rendered":"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas"},"content":{"rendered":"\n<p><strong>Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that its <strong>trispecific antibody ZG006 (alveltamig)<\/strong> has been granted <strong>Orphan Drug Designation (ODD)<\/strong> by the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of <strong>neuroendocrine carcinomas (NECs)<\/strong>. The designation provides <strong>tax\u2011credit incentives, market\u2011exclusivity extensions, and regulatory support<\/strong> for the first\u2011in\u2011class therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-amp-regulatory-summary\">Transaction &amp; Regulatory Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Suzhou\u202fZelgen\u202fBiopharmaceuticals Co., Ltd. (SHA: 688266)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ZG006 (alveltamig) \u2013 trispecific T\u2011cell engager<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neuroendocrine carcinomas (NEC)<\/td><\/tr><tr><td><strong>FDA Action<\/strong><\/td><td>Orphan Drug Designation (ODD) \u2013 20\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>Other Approvals<\/strong><\/td><td>Clinical\u2011trial clearance from FDA (IND) and China NMPA<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Bispecific\/Multispecific antibody R&amp;D platform<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Dual epitopes of DLL3 (Notch pathway) + CD3 (T\u2011cell)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-science-amp-mechanism\">Science &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trispecific Architecture:<\/strong> ZG006 simultaneously binds <strong>two distinct DLL3 epitopes<\/strong> (over\u2011expressed on NEC cells) and <strong>CD3<\/strong> on T\u2011cells, forming a stable immunologic synapse that redirects cytotoxic T\u2011cells to the tumor.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Potential:<\/strong> By engaging two tumor\u2011associated epitopes, ZG006 aims to overcome <strong>antigen\u2011escape<\/strong> mechanisms that limit conventional bispecifics.<\/li>\n\n\n\n<li><strong>Pre\u2011clinical Proof\u2011point:<\/strong> In murine xenograft models of DLL3\u2011positive NEC, a single dose of ZG006 produced <strong>>\u202f80\u202f% tumor regression<\/strong> with durable responses lasting >\u202f30\u202fdays.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Expected Date<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202fI IND\u2011enrollment (US)<\/strong><\/td><td>Q1\u202f2026<\/td><\/tr><tr><td><strong>Phase\u202fI IND\u2011enrollment (China)<\/strong><\/td><td>Q2\u202f2026<\/td><\/tr><tr><td><strong>Interim analysis (dose\u2011escalation)<\/strong><\/td><td>Q4\u202f2026<\/td><\/tr><tr><td><strong>Phase\u202fII\/III launch (US &amp; China)<\/strong><\/td><td>2028\u20112029 (contingent on Phase\u202fI safety)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-financial-outlook\">Market Impact &amp; Financial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NEC Landscape:<\/strong> Neuroendocrine carcinomas affect ~\u202f150,000 patients globally, with <strong>limited targeted options<\/strong> and a 5\u2011year survival &lt;\u202f15\u202f%.<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Assuming a <strong>U.S. market share of 5\u202f%<\/strong> after approval, ZG006 could generate <strong>\u2248\u202fUS$300\u202fmillion<\/strong> in annual sales (based on a projected price of US$150,000 per patient course).<\/li>\n\n\n\n<li><strong>Orphan Incentives:<\/strong> FDA ODD grants <strong>7\u2011year market exclusivity<\/strong> and <strong>tax credits up to US$2\u202fmillion<\/strong> for clinical\u2011trial expenses, improving the project\u2019s net\u2011present\u2011value.<\/li>\n\n\n\n<li><strong>Funding:<\/strong> Zelgen has earmarked <strong>RMB\u202f200\u202fmillion<\/strong> (~US$28\u202fmillion) for Phase\u202fI\u2011II activities, with additional capital being explored through strategic partnerships and secondary listings.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding regulatory outcomes, clinical development, and commercial expectations for ZG006. Actual results may differ due to risks including clinical\u2011trial results, regulatory approvals, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its trispecific antibody ZG006 (alveltamig) has been&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48431,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[28,24,905,246],"class_list":["post-48430","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-multi-specific-antibodies","tag-rare-orphan-disease-drugs","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its trispecific antibody ZG006 (alveltamig) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinomas (NECs). The designation provides tax\u2011credit incentives, market\u2011exclusivity extensions, and regulatory support for the first\u2011in\u2011class therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48430\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas\" \/>\n<meta property=\"og:description\" content=\"Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its trispecific antibody ZG006 (alveltamig) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinomas (NECs). The designation provides tax\u2011credit incentives, market\u2011exclusivity extensions, and regulatory support for the first\u2011in\u2011class therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48430\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T06:05:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas\",\"datePublished\":\"2025-11-17T06:05:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430\"},\"wordCount\":383,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704.webp\",\"keywords\":[\"Multi-specific antibodies\",\"Rare \\\/ orphan disease drugs\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48430#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48430\",\"name\":\"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704.webp\",\"datePublished\":\"2025-11-17T06:05:36+00:00\",\"description\":\"Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its trispecific antibody ZG006 (alveltamig) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinomas (NECs). The designation provides tax\u2011credit incentives, market\u2011exclusivity extensions, and regulatory support for the first\u2011in\u2011class therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48430\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48430#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its trispecific antibody ZG006 (alveltamig) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinomas (NECs). The designation provides tax\u2011credit incentives, market\u2011exclusivity extensions, and regulatory support for the first\u2011in\u2011class therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48430","og_locale":"en_US","og_type":"article","og_title":"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas","og_description":"Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its trispecific antibody ZG006 (alveltamig) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinomas (NECs). The designation provides tax\u2011credit incentives, market\u2011exclusivity extensions, and regulatory support for the first\u2011in\u2011class therapy.","og_url":"https:\/\/flcube.com\/?p=48430","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T06:05:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48430#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48430"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas","datePublished":"2025-11-17T06:05:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48430"},"wordCount":383,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48430#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704.webp","keywords":["Multi-specific antibodies","Rare \/ orphan disease drugs","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48430#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48430","url":"https:\/\/flcube.com\/?p=48430","name":"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48430#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48430#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704.webp","datePublished":"2025-11-17T06:05:36+00:00","description":"Suzhou\u202fZelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its trispecific antibody ZG006 (alveltamig) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinomas (NECs). The designation provides tax\u2011credit incentives, market\u2011exclusivity extensions, and regulatory support for the first\u2011in\u2011class therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48430#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48430"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48430#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704.webp","width":1080,"height":608,"caption":"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48430#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen Biopharma\u2019s ZG006 (Alveltamig) Receives FDA Orphan\u2011Drug Designation for Neuroendocrine Carcinomas"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48430"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48430\/revisions"}],"predecessor-version":[{"id":48432,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48430\/revisions\/48432"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48431"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}